Current role of sildenafil in the management of erectile dysfunction


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Sildenafil is the first phosphodiesterase type 5 inhibitor (PDE-5), used in the management of erectile dysfunction (ED). The effectiveness and safety of the original drug have been studied most extensively among ED medications. Sildenafil has been successfully used for ED of different etiology and severity. To date, this PDE-5 remains the drug of choice for many patients with erectile dysfunction.

Full Text

Restricted Access

About the authors

N. D Akhvlediani

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: nikandro@maii.ru
Dr.Med.Sci., Professor at the Department of Uroiogy

I. P Matyukhov

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: ва. Россия; e-maii: matyukhovip@gmaii.com
Ph.D., Physician at the Diagnostic Department, Research Institute for Uronephroiogy and Human Reproductive Heaith

References

  1. Braun M., Wassmer G., Klotz T., Reifenrath B., Mathers M., Engelmann U. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int JImpot Res. 2000 Dec;12(6):305-311. doi: 10.1038/sj.ijir.3900622.
  2. Papaharitou S., Athanasiadis L., Nakopoulou E., Kirana P., Portseli A., Iraklidou M., Hatzimouratidis K., Hatzichristou D. Erectile dysfunction and premature ejaculation are the most frequently self-reported sexual concerns: profiles of 9,536 men calling a helpline. Eur Urol. 2006;49:557-563. doi: 10.1016/j.eururo.2005.09.023.
  3. Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., McKinlay J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. 1994;151:54-61.
  4. Aytac I.A., McKinlay J.B., Krane R.J. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50-56
  5. Kostis J.B., Jackson G., Rosen R., Barrett-Connor E., Billups K., Burnett A.L., Carson C. 3rd, Cheitlin M., Debusk R., Fonseca V., Ganz P., Goldstein I., Guay A., Hatzichristou D., Hollander J.E., Hutter A., Katz S., Kloner R.A., Mittleman M., Montorsi F., Montorsi P., Nehra A., Sadovsky R., Shabsigh R. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005 Jul 15;96(2):313-321. Doi: 10.1016/j. amjcard.2005.03.065
  6. Пушкарь Д.Ю., Камалов А.А., Аль-Шукри С.Х., Еркович А.А., Коган М.И., Павлов В.Н., Журавлев В.Н., Берников А.Н. Анализ результатов эпидемиологического исследования распространенности эректильной дисфункции в Российской Федерации. Урология. 2012;6:5-9
  7. Hatzichristou D.G., Pescatori E.S. Current treatments and emerging therapeutic approaches in male erectile dysfunction. BJU Int. 2001; 88(Suppl. 3):11-17.
  8. Lewis R., Bennett C.J., Borkon W.D., Boykin W.H., Althof S.E., Stecher V.J., Siegel R.L. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology. 2001;57:960-965.
  9. Steers W., Guay A.T., Leriche A., Gingell C., Hargreave T.B., Wright P.J., Price D.E., Feldman R.A. Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment. Int J. Impot Res. 2001;13:261-267.
  10. McVary K.T. Erectile dysfunction. New Engl. J. Med. 2007; 357: 2472-2481. doi: 10.1056/NEJMcp067261.
  11. Vardi Y., Bulus M., Reisner S., Nassar S., Aboud L., Sprecher E., Gruenwald I. Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. Eur Urol. 2003; 43(5):544-551.
  12. Lokshin K.L. Comparative characteristics of sildenafil and other inhibitors of phosphodiesterase type 5 in the treatment of patients with erectile dysfunction (review ofthe literature). Russian Medical Journal. 2013;18:936- 939 (Локшин К.Л. Сравнительная характеристика силденафила и других ингибиторов фосфодиэстеразы 5-го типа в лечении больных эректильной дисфункцией (обзор литературы). Русский медицинский журнал. 2013;18:936-939).
  13. Carson CC III. Sildenafil: A 4-Year Update in the Treatment of 20 Million Erectile Dysfunction Patients. Current Urology Reports 2003, 4:488-496.
  14. Kloner RA., Brown M., Prisant L.M. Collins M. Effect of sildenafil in patients with erectile dysfunction takin antihypertensive therapy. AJH 2001; 14:70-73.
  15. Carson C.C., Burnett A.L., Levine L.A., Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology. 2002 Sep; 60 (2 Suppl 2):12-27.
  16. Padma-Nathan H., Stecher V., Sweeney M., Orazem J. Tseng L.-J., Deriesthal H. Minimal time to successful intercourse after sildenafil citrate: results of randomized, double-blind, placebo-controlled trial. Urology. 2003; 62:400-403.
  17. John P.M., Hassan T.A., Rienow J.347 Understanding the Sexual Habits of Men Taking Medication for Erectile Dysfunction (ED): Survey Results From 7 Countries. J. Sex Med 2017:14:1:S102. Doi: https://doi.org/10.1016/j. jsxm.2016.11.235.
  18. Claes H., Opsomer R.J., Andrianne R., Vanbelle S., Albert A., Vanderdonck F. Characteristics and expectations of patients with erectile dysfunction: results of the SCORED study. Int J. Impot Res. 2008;20(4):418-424. Doi: 10.1038/ ijir.2008.7.
  19. Тарасов Н.И., Бавильский В.Ф., Матыгин А.С. Длительная монотерапия силденафила цитратом при различных формах эректильной дисфункции. Клиническая фармакология и терапия. 2009;18(2):34-37
  20. Fusco F., Razzoli E., Imbimbo C., Rossi A., Verze P., Mirone V. A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition. BJU Int. 2010 Jun;105(12):1634-1639. doi: 10.1111/j.1464-410X.2010.09244.x.
  21. Cappelleri J.C., Althof S.E., Siegel R.L., Shpilsky A., Bell S.S., Duttagupta S. Development and validation of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction. Int J. Impot Res. 2004 Feb;16(1):30-38. doi: 10.1038/sj.ijir.3901095.
  22. Raina R., Lakin M.M., Agarwal A., Sharma R., Goyal K.K., Montague D.K., Klein E., Zippe C.D. Long-term effect of siidenafii citrate on erectiie dysfunction after radicai prostatectomy: 3-year foiiow-up. Uroiogy. 2003;62(1):110-115.
  23. Hong E.K., Lepor H., McCullough A.R. Time dependent patient satisfaction with siidenafii for erectiie dysfunction (ED) after nerve-sparing radicai retropubic prostatectomy (RRP). Int J. Impot Res. 1999 Sep;11(Suppi 1):S15-22.
  24. Padma-Nathan H., McCullough A., Forest C. Erectiie dysfunction secondary to nerve-sparing radicai retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novei prevention strategies. Curr Uroi Rep. 2004;5(6):467-471.
  25. Jannini E.A., Isidori A.M., Gravina G.L., Aversa A., Balercia G., Bocchio M., Boscaro M., Carani C., Corona G., Fabbri A., Foresta C., Forti G., Francavilla S., Granata A.R., Maggi M., Mansani R., Palego P., Spera G., Vetri M., Lenzi A. The ENDOTRIAL study: a spontaneous, open-iabei, randomized, muiticenter, crossover study on the efficacy of siidenafii, tadaiafii and vardenafii in the treatment of erectiie dysfunction. J. Sex Med 2009;6:2547- 2560. doi: 10.1111/j.1743-6109.2009.01375.x.
  26. Hatzimouratidis K., Giuliano F., Moncada I., Muneer A., Salonia A., Verze P., Parnham A., Serefoglu E.C. EAU Guideiines on Erectiie Dysfunction, Premature Ejacuiation, Peniie Curvature and Priapism, 2017.
  27. McMurray J.G., Feldman R.A., Auerbach S.M., Deriesthal H., Wilson N. Muiticenter Study Group. Long-term safety and effectiveness of siidenafii citrate in men with erectiie dysfunction. Ther Ciin Risk Manag. 2007;3(6):975-981.
  28. Montorsi F., Briganti A., Salonia A., et al. Erectiie dysfunction prevaience, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographicaiiy documented coronary artery disease. Eur Uroi. 2003;44:360-364.
  29. Jackson G., Boon N., Eardley I., Kirby M., Dean J., Hackett G., Montorsi P., Montorsi F., Vlachopoulos C., Kloner R., Sharlip I., Miner M. Erectiie dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int. J. Ciin. Pract. 2010;64(7):848-857. doi: 10.1111/j.1742-1241.2010.02410.x.
  30. Boshier A., Wilton L.V., Shakir S.A. Evaiuation of the safety of siidenafii for maie erectiie dysfunction: experience gained in generai practice use in Engiand in 1999. BJU Int. 2004;93:796-801. doi: 10.1111/j.1464-410X.2003.04744.x.
  31. Katz S.D., Balidemaj K., Homma S., Wu H., Wang J., Maybaum S. Acute type 5 phosphodiesterase inhibition with siidenafii enhances fiow-mediated vasodiiation in patients with chronic heart faiiure. J. Am Coii Cardioi. 2000;36:845-851.
  32. Desouza C., Parulkar A., Lumpkin D., Akers D., Fonseca V.A. Acute and proionged effects of siidenafii on brachiai artery flow-mediated diiatation in type 2 diabetes. Diabetes Care. 2002;25:1336-1339.
  33. Gori T., Sicuro S., Dragoni S., Donati G., Forconi S., Parker J.D. Siidenafii prevents endotheiiai dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channeis: a human in vivo study. Circuiation. 2005;111:742-746. doi: 10.1161/01. CIR.0000155252.23933.2D.
  34. Hirata K., Adji A., Vlachopoulos C., O’Rourke M.F. Effect of siidenafii on cardiac performance in patients with heart faiiure. Am J. Cardioi. 2005;96:1436-1440. doi: 10.1016/j.amjcard.2005.06.091.
  35. Gillies H.C., Roblin D., Jackson G. Coronary and systemic hemodynamic effects of siidenafii citrate: from basic science to ciinicai studies in patients with cardiovascuiar disease. Int J. Cardioi. 2002;86:131-141.
  36. Vlachopoulos C., Hirata K., O’Rourke M.F. Effect of siidenafii on arteriai stiffness and wave reflection. Vasc Med. 2003;8:243-248. doi: 10.1191/1358863x03vm509ra.
  37. Kukreja R.C., Ockaili R., Salloum F., Yin C., Hawkins J., Das A., Xi L. Cardioprotection with phosphodiesterase-5 inhibition-a novei preconditioning strategy. J. Moi Ceii Cardioi. 2004;36:165-173. doi: 10.1016/j.yjmcc.2003.11.001.
  38. Webster L.J., Michelakis E.D., Davis T., et al. Use of siidenafii for safe improvement of erectiie function and quaiity of iife in men with New York Heart Association ciasses II and III congestive heart faiiure: a prospective, piacebo-controiied, doubie-biind crossover triai. Arch Intern Med. 2004;164:514-520. doi: 10.1001/archinte.164.5.514.
  39. Borlaug B.A., Melenovsky V., Marhin T., Fitzgerald P., Kass D.A. Siidenafii inhibits beta-adrenergic-stimuiated cardiac contractiiity in humans. Circuiation. 2005; 112:2642-2649. doi: 10.1161/CIRCULATI0NAHA. 105.540500.
  40. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., Bedja D., Gabrielson K.L., Wang Y., Kass D.A. Chronic inhibition of cyciic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222. doi: 10.1038/nm1175.
  41. Ghofrani H.A., Voswinckel R., Reichenberger F., Olschewski H., Haredza P., Karadaq B., Schermuly R.T., Weissmann N., Seeger W., Grimminger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with puimonary arterial hypertension: a randomized prospective study. J. Am Coli Cardiol. 2004;44(7):1488-1496. doi: 10.1016/j.jacc.2004.06.060.
  42. Lee A.J., Chiao T.B., Tsang M.P. Sildenafil for Puimonary Hypertension. Ann Pharmacother 2005;39(5):869-884. doi: 10.1345/aph.1E426.
  43. Rosengarten B., Schermuly R.T., Voswinckel R., Kohstall M.G., Olschewski H., Weissmann N., Seeger W., Kaps M., Grimminger F., Ghofrani H.A. Sildenafil improves dynamic vascu-iar function in the brain: studies in patients with puimonary hypertension. Cerebrovasc, Dis 2006;21(3):194-200. doi: 10.1159/000090555.
  44. Chua R., Keogh A., Miyashita M. Novei use of slidenafil in the treatment of portopuimon-ary hypertension. J. Heart Lung Transplant. 2005;24(4):498- 500. doi: 10.1016/j.heaiun.2004.01.017.
  45. Galiè N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., Simonneau G.; Slidenafil Use in Puimonary Arteriai Hypertension (SUPER) Study Group. Slidenafil citrate therapy for puimonary arteriai hypertension. N. Engi J. Med. 2005 Nov 17;353(20):2148-2157. Erratum in: N. Engi J. Med. 2006;354(22):2400-2401. doi: 10.1056/NEJMoa050010.
  46. Тарловская Е.И. Генерики в реальной клинической практике. Артериальная гипертензия. 2009; 5(4):512-515
  47. Хубиева М.Ю. Проблемы качества и терапевтической эквивалентности дженериков. Здравоохранение. 2010;11:5-27
  48. Верткин А.Л., Талибов О.Б. Генерики и эквивалентность - что стоит за терминами. Неотложная терапия. 2004;1-2:16-17

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies